Analysis of Epstein-Barr Virus (EBV) and PD-L1 Expression in Nasopharyngeal Carcinoma Patients in a Non-Endemic Region.

Int J Mol Sci · 2022 · PMC9569432 · PMID 36233023

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Ma and colleagues reported in a phase II trial using nivolumab in metastatic and/or refractory NPC that 33% of PD-L1-positive patients responded to nivolumab, while only 13% of those with PD-L1 negative tumors responded; however, this did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.